Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives
Diabetes mellitus (DM) is a multifaceted disorder with a pandemic spread and a remarkable burden of cardiovascular mortality and morbidity. Diabetic cardiomyopathy (DBCM) has been increasingly recognized as the development of cardiac dysfunction, which is accompanied by heart failure (HF) symptoms i...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/1/134 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587736811307008 |
|---|---|
| author | Elina Khattab Michaelia Kyriakou Elena Leonidou Stefanos Sokratous Angeliki Mouzarou Michael M. Myrianthefs Nikolaos P. E. Kadoglou |
| author_facet | Elina Khattab Michaelia Kyriakou Elena Leonidou Stefanos Sokratous Angeliki Mouzarou Michael M. Myrianthefs Nikolaos P. E. Kadoglou |
| author_sort | Elina Khattab |
| collection | DOAJ |
| description | Diabetes mellitus (DM) is a multifaceted disorder with a pandemic spread and a remarkable burden of cardiovascular mortality and morbidity. Diabetic cardiomyopathy (DBCM) has been increasingly recognized as the development of cardiac dysfunction, which is accompanied by heart failure (HF) symptoms in the absence of obvious reasons like ischemic heart disease, hypertension, or valvulopathies. Several pathophysiological mechanisms have been proposed, including metabolic disorders (e.g., glycation products), oxidative stress, low-grade inflammation, mitochondrial dysfunction, etc., which should guide the development of new therapeutic strategies. Up to now, HF treatment has not differed between patients with and without diabetes, which limits the expected benefits despite the high cardiovascular risk in the former group. However, DBCM patients may require different management, which prioritize anti-diabetic medications or testing other novel therapies. This review aims to appraise the challenges and prospectives of the individualized pharmaceutical therapy for DBCM. |
| format | Article |
| id | doaj-art-c3d34115087a40399128b1797002d9dd |
| institution | Kabale University |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-c3d34115087a40399128b1797002d9dd2025-01-24T13:45:31ZengMDPI AGPharmaceuticals1424-82472025-01-0118113410.3390/ph18010134Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and ProspectivesElina Khattab0Michaelia Kyriakou1Elena Leonidou2Stefanos Sokratous3Angeliki Mouzarou4Michael M. Myrianthefs5Nikolaos P. E. Kadoglou6Department of Cardiology, Nicosia General Hospital, 2029 Nicosia, CyprusDepartment of Cardiology, Nicosia General Hospital, 2029 Nicosia, CyprusDepartment of Cardiology, Limassol General Hospital, 3304 Limassol, CyprusDepartment of Cardiology, Nicosia General Hospital, 2029 Nicosia, CyprusDepartment of Cardiology, Pafos General Hospital, 8026 Paphos, CyprusDepartment of Cardiology, Nicosia General Hospital, 2029 Nicosia, CyprusMedical School, University of Cyprus, 1678 Nicosia, CyprusDiabetes mellitus (DM) is a multifaceted disorder with a pandemic spread and a remarkable burden of cardiovascular mortality and morbidity. Diabetic cardiomyopathy (DBCM) has been increasingly recognized as the development of cardiac dysfunction, which is accompanied by heart failure (HF) symptoms in the absence of obvious reasons like ischemic heart disease, hypertension, or valvulopathies. Several pathophysiological mechanisms have been proposed, including metabolic disorders (e.g., glycation products), oxidative stress, low-grade inflammation, mitochondrial dysfunction, etc., which should guide the development of new therapeutic strategies. Up to now, HF treatment has not differed between patients with and without diabetes, which limits the expected benefits despite the high cardiovascular risk in the former group. However, DBCM patients may require different management, which prioritize anti-diabetic medications or testing other novel therapies. This review aims to appraise the challenges and prospectives of the individualized pharmaceutical therapy for DBCM.https://www.mdpi.com/1424-8247/18/1/134diabetic cardiomyopathyheart failureARNIsSGLT2ipharmaceutical therapy |
| spellingShingle | Elina Khattab Michaelia Kyriakou Elena Leonidou Stefanos Sokratous Angeliki Mouzarou Michael M. Myrianthefs Nikolaos P. E. Kadoglou Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives Pharmaceuticals diabetic cardiomyopathy heart failure ARNIs SGLT2i pharmaceutical therapy |
| title | Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives |
| title_full | Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives |
| title_fullStr | Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives |
| title_full_unstemmed | Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives |
| title_short | Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives |
| title_sort | critical appraisal of pharmaceutical therapy in diabetic cardiomyopathy challenges and prospectives |
| topic | diabetic cardiomyopathy heart failure ARNIs SGLT2i pharmaceutical therapy |
| url | https://www.mdpi.com/1424-8247/18/1/134 |
| work_keys_str_mv | AT elinakhattab criticalappraisalofpharmaceuticaltherapyindiabeticcardiomyopathychallengesandprospectives AT michaeliakyriakou criticalappraisalofpharmaceuticaltherapyindiabeticcardiomyopathychallengesandprospectives AT elenaleonidou criticalappraisalofpharmaceuticaltherapyindiabeticcardiomyopathychallengesandprospectives AT stefanossokratous criticalappraisalofpharmaceuticaltherapyindiabeticcardiomyopathychallengesandprospectives AT angelikimouzarou criticalappraisalofpharmaceuticaltherapyindiabeticcardiomyopathychallengesandprospectives AT michaelmmyrianthefs criticalappraisalofpharmaceuticaltherapyindiabeticcardiomyopathychallengesandprospectives AT nikolaospekadoglou criticalappraisalofpharmaceuticaltherapyindiabeticcardiomyopathychallengesandprospectives |